在患有复发或耐药腹部神经内分泌瘤的患者中使用恩丁诺斯塔特
Jacob K Jamison1, Mengxi Zhou2, Edward P Gelmann3
1Weill Cornell Medical College, New York, NY, United States.
The oncologist
|June 17, 2024
概括
作为一种组织素脱乙酶抑制剂的恩丁诺斯塔特在患有晚期胃肠道胰腺神经内分泌瘤 (GEP-NETs) 的患者中显著减少了瘤生长. 这项研究突出了内因诺斯塔特的作用.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 表观遗传学 在表观遗传学中,表观遗传学是指表观遗传学.
背景情况:
- 胃肠道胰腺神经内分泌瘤 (GEP-NETs) 很少见,通常是转移性,除了体静止素类似物之外,治疗选择有限.
- 基因组修饰,包括基因组脱乙酶 (HDAC) 抑制剂向的基因组修饰,在癌症的发展和进展中起作用.
研究的目的:
- 评价HDAC抑制剂恩丁诺斯塔特在患有复发或耐药腹部神经内分泌瘤 (NETs) 的患者中的疗效和安全性.
- 评估氨酸对GEP-NETs的抗增殖作用.
主要方法:
- 进行了一项II期临床研究,以评估腹部NET患者的肠静止剂的疗效和安全性.
- 患者每周接受 5 毫克的恩提诺斯塔特,直到疾病进展或毒性. 在治疗前和治疗期间比较瘤生长率.
主要成果:
- 由于早期终止,只有4名可评估的患者被纳入. 所有4人均实现了稳定的疾病 (SD) 延长了研究时间.
- 瘤生长率在肠静止剂上显著降低,从治疗前的17%到68%的比率.
- 与治疗相关的毒性通常是可以控制的,包括中性衰竭和低度血.
结论:
- 在患有复发性/耐药性腹部NET的患者中,每周使用的氨酸 (5mg) 显示出长时间的稳定疾病和减少的瘤生长率 (32%83%).
- 在这个患者群体中,恩替诺斯塔特表现出可接受的安全性.
更多相关视频
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
10.5K
10:28Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT
Published on: January 22, 2018
11.1K
相关概念视频
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
159
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
159
01:27Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
192
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
192
01:15Drugs that Stabilize Microtubules
2.0K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.0K
02:57Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
01:26Peptic Ulcer Disease IV: Management
87
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
87